Indianapolis’ newest publicly company, Point Biopharma Inc., is the latest player in a field expected to see explosive growth as doctors and researchers look for new ways to shrink tumors.
Read More
Just 12 years after opening to great fanfare, the future of the $150 million center, a partnership between the Indiana University School of Medicine and Indiana University Health, is full of questions.
Read More
Hardesty, 51, said operations at his culinary business, Studio C, will be scaled back while he undergoes treatment over the next several months.
Read More
Indiana University Health’s new Schwarz Cancer Center is the latest addition to a crowded landscape of cancer centers and hospital oncology programs popping up around central Indiana.
Read MoreIt’s a big moment for On Target Laboratories, an 11-year-old biotech based in West Lafayette. The FDA approval marks the company’s first novel compound to get across the finish line. The drug is marketed under the brand name Cytalux.
Few such drugs are approved now, but the approach is predicted to become a new way to treat patients with other hard-to-reach or inoperable cancers.
Dee Alderman’s doctors told her in November, as cases heated up, to stay home completely; her husband and son decontaminate every time they come in the house.
Merus N.V. specializes is so-called CD3 engaging T-cell therapies, a growing area of cancer research, based on immunotherapy, or using the immune system’s T cells to find and shrink tumors
The grant will help fund an ongoing study to evaluate long-term health outcomes for cancer patients who receive life-saving chemotherapy treatments that often have difficult side effects.
Estimates by the National Cancer Institute show there will be 10,000 more breast and colorectal cancer deaths over the next decade than would have been expected without the coronavirus. The director said that estimate was perhaps too conservative.
Development Corp., is helping raise money for a women-focused cancer research initiative. The campaign, which will run through June, is in its second year.
Researchers on Wednesday reported the largest-ever one-year decline in the U.S. cancer death rate, a drop they credited to advances in lung-tumor treatments.
The drug, called pegilodecakin, had been seen as a promising treatment for one of the deadliest types of cancer, and was the lead product in Lilly’s $1.6 billion acquisition of Armo BioSciences last year.
The treatment costs $375,000 or $475,000, depending on whether it is used for advanced lymphoma or pediatric leukemia. Hospital stays can add hundreds of thousands of dollars to the cost of care.
The cancer center, opened in 2008, is now one of just 51 “comprehensive cancer centers” in the nation and the only one in Indiana.
Array’s stock was already at a record before the deal announcement, following the company’s news last month of positive clinical trial results using Braftovi and Mektovi with Indianapolis-based Eli Lilly and Co.’s Erbitux.
Kansas-based Aratana Therapeutics has three treatments approved by the U.S. Food and Drug Administration and is working on drugs for a range of disease fields, including cancer.
Long a leader in diabetes and neuroscience drugs, Eli Lilly and Co. is pushing hard and spending record sums to turbocharge its oncology business, potentially a huge growth area.
Bristol-Myers Squibb Co. on Friday won a shareholder vote to approve its takeover of Celgene Corp., paving the way to close the largest pharmaceutical merger in history and create a cancer-drug giant.
Lartruvo shouldn’t be started in new patients, and those patients already taking it should ask their doctors if they should continue, U.S. regulators said, following a key study that failed to show the medicine prolonged lives.
Lower smoking rates are translating into fewer deaths. Advances in early detection and treatment also are having a positive impact, experts say.
The researchers are testing the effectiveness of a small, targeted molecule to prevent or reverse chemotherapy-induced peripheral neuropathy—a nerve problem that causes pain, numbness and tingling.
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
The West Lafayette biotech firm’s stock traded as low as $1.41 last fall, following multiple setbacks and restructurings. But the stock had soared to $24 Thursday morning after news that it would be acquired by Novartis.
